Labarrere Carlos A, Ortiz Miguel A, Ruzmetov Nargiz, Sosa Marcelo J, Campana Gonzalo, Terry Colin, Baldridge Lee Ann, Antonopoulos Roula, DiCarlo Hector L
Division of Experimental Pathology, Methodist Research Institute, Clarian Health Partners, Indianapolis, Indiana 46202, USA.
J Heart Lung Transplant. 2006 Oct;25(10):1213-22. doi: 10.1016/j.healun.2006.06.013. Epub 2006 Sep 15.
The role of a hypercoagulable microvasculature in the development of cardiac allograft vasculopathy (CAV) after heart transplantation in humans is not well understood. The aim of this study was to identify an animal model by which to further evaluate the role of coagulation in the pathogenesis of CAV.
Adult male PVG (RT-1(c)) rats were transplanted into ACI (RT-1(av1)) recipients (n = 29). ACI donors into ACI recipients (n = 31) and rats with a sham operation (n = 33) served as controls. All rats received cyclosporine (10 mg/kg/day) on Days 0 to 9 after surgery. Grafts and native hearts were harvested at 10 days to 3 months after surgery. Hearts were processed for immunohistochemistry and light microscopy. A hypercoagulable microvasculature was defined as presence of microvascular fibrin and capillary antithrombin. CAV was defined as the presence of concentric intimal proliferation and chronic inflammatory infiltrate in the arterial intima, and assessed by computer-assisted image analysis.
Donor and recipient hearts from PVG-ACI rats showed high levels of fibrin (donors 7.5% to 21.9%, recipients 5.1% to 20.2%) and antithrombin (donors 5.2% to 27.9%, recipients 3.3% to 20.8%) at 10 days to 3 months post-transplant. ACI-ACI donor and recipient hearts had lower deposition of fibrin (donors 0.9% to 9.9%, recipients 0% to 4.0%) and antithrombin (donors 1.4% to 15.2%, recipients 0.8% to 4.5%). Hearts from sham-operated rats had negligible amounts of fibrin (0% to 1.5%) and antithrombin (0% to 2.8%). There was a strong association (p < 0.001) between presence of fibrin and capillary antithrombin and development of CAV.
A hypercoagulable microvasculature in a rat model of heart transplantation was associated with development of CAV, as found in humans.
高凝性微血管在人类心脏移植后心脏移植血管病变(CAV)发展中的作用尚未完全明确。本研究的目的是确定一种动物模型,以便进一步评估凝血在CAV发病机制中的作用。
将成年雄性PVG(RT-1(c))大鼠移植到ACI(RT-1(av1))受体中(n = 29)。将ACI供体移植到ACI受体中(n = 31)以及进行假手术的大鼠(n = 33)作为对照。所有大鼠在术后第0至9天接受环孢素(10 mg/kg/天)治疗。在术后10天至3个月采集移植物和自体心脏。对心脏进行免疫组织化学和光学显微镜检查。高凝性微血管定义为存在微血管纤维蛋白和毛细血管抗凝血酶。CAV定义为动脉内膜出现同心性内膜增生和慢性炎性浸润,并通过计算机辅助图像分析进行评估。
在移植后10天至3个月,PVG-ACI大鼠的供体和受体心脏显示出高水平的纤维蛋白(供体7.5%至21.9%,受体5.1%至20.2%)和抗凝血酶(供体5.2%至27.9%,受体3.3%至20.8%)。ACI-ACI供体和受体心脏的纤维蛋白沉积较低(供体0.9%至9.9%,受体0%至4.0%),抗凝血酶沉积也较低(供体1.4%至15.2%,受体0.8%至4.5%)。假手术大鼠的心脏中纤维蛋白(0%至1.5%)和抗凝血酶(0%至2.8%)的含量可忽略不计。纤维蛋白和毛细血管抗凝血酶的存在与CAV的发展之间存在强烈关联(p < 0.001)。
正如在人类中发现的那样,心脏移植大鼠模型中的高凝性微血管与CAV的发展相关。